Epigenetic inactivation of the placentally imprinted tumor suppressor gene TFPI2 in prostate carcinoma

Cancer Genomics and Proteomics

Volumn 7, Issue 2, 2010, Pages 51-60

  Ribarska, Teodora ^a   Ingenwerth, Marc ^a   Goering, Wolfgang ^a   Engers, Rainer ^a   Schulz, Wolfgang A ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Bisulphite sequencing; Chromatin immunoprecipitation; DNA methylation; Imprinting; Prostate cancer; TFPI2

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ARYLDIALKYLPHOSPHATASE 2; BISULFITE; EPSILON SARCOGLYCAN; PLACENTA PROTEIN 5; TISSUE FACTOR PATHWAY INHIBITOR;

ARTICLE; CANCER CELL CULTURE; CHROMATIN IMMUNOPRECIPITATION; CHROMOSOME 7Q; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA METHYLATION; EPIGENETICS; GENE CLUSTER; GENE EXPRESSION; GENE INACTIVATION; HUMAN; HUMAN TISSUE; PROSTATE CARCINOMA; PROTEIN MODIFICATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; TUMOR SUPPRESSOR GENE;

EID: 77950937747     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Schulz WA and Hoffmann MJ: Epigenetic mechanisms in the biology of prostate cancer. Semin Cancer Biol 19: 172-180, 2009.
2. Cooper CS and Foster CS: Concepts of epigenetics in prostate cancer development. Br J Cancer 100: 240-245, 2009.
3. McCabe MT, Brandes JC and Vertino PM: Cancer DNA methylation: molecular mechanisms and clinical implications. Clin Cancer Res 15: 3927-3937, 2009.
4. Hoffmann MJ and Schulz WA: Causes and consequences of DNA hypomethylation in human cancer. Biochem Cell Biol 83: 296-321, 2005.
5. Yegnasubramanian S, Haffner MC, Zhang Y, Gurel B, Cornish TC, Wu Z, Irizarry RA, Morgan J, Hicks J, DeWeese TL, Isaacs WB, Bova GS, De Marzo AM and Nelson WG: DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res 68: 8954-8967, 2008.
6. Wilson AS, Power BE and Molloy PL: DNA hypomethylation and human diseases. Biochim Biophys Acta 1775: 138-162, 2007.
7. Jelinic P and Shaw P: Loss of imprinting and cancer. J Pathol 211: 261-268, 2007.
8. Curchoe CL, Zhang S, Yang L, Page R and Tian XC: Hypomethylation trends in the intergenic region of the imprinted IGF2 and H19 genes in cloned cattle. Anim Reprod Sci 116: 213-225, 2009.
9. Owen CM and Segars JH Jr: Imprinting disorders and assisted reproductive technology. Semin Reprod Med 27: 417-428, 2009.
10. Murrell A: Genomic imprinting and cancer: from primordial germ cells to somatic cells. Scientific World J 6: 1888-1910, 2006.
11. Sasaki H, Ishihara K and Kato R: Mechanisms of Igf2/H19 imprinting: DNA methylation, chromatin and long-distance gene regulation. J Biochem 127: 711-715, 2000.
12. Wagschal A and Feil R: Genomic imprinting in the placenta. Cytogenet Genome Res 113: 90-98, 2006.
13. Wagschal A, Sutherland HG, Woodfine K, Henckel A, Chebli K, Schulz R, Oakey RJ, Bickmore WA and Feil R: G9a histone methyltransferase contributes to imprinting in the mouse placenta. Mol Cell Biol 28: 1104-1113, 2008.
14. Dindot SV, Person R, Strivens M, Garcia R and Beaudet AL: Epigenetic profiling at mouse imprinted gene clusters reveals novel epigenetic and genetic features at differentially methylated regions. Genome Res 19: 1374-1383, 2009.
15. Sanz LA, Chamberlain S, Sabourin JC, Henckel A, Magnuson T, Hugnot JP, Feil R and Arnaud P: A mono-allelic bivalent chromatin domain controls tissue-specific imprinting at Grb10. EMBO J 27: 2523-2532, 2008.
16. Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, Cuff J, Fry B, Meissner A, Wernig M, Plath K, Jaenisch R, Wagschal A, Feil R, Schreiber SL and Lander ES: A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125: 315-326, 2006.
17. Rodriguez J, Munoz M, Vives L, Frangou CG, Groudine M and Peinado MA: Bivalent domains enforce transcriptional memory of DNA methylated genes in cancer cells. Proc Natl Acad Sci USA 105: 19809-19814, 2008.
18. Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, Zimmerman J, Eden E, Yakhini Z, Ben-Shushan E, Reubinoff BE, Bergman Y, Simon I and Cedar H: Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 39: 232-236, 2007.
19. Cui H: Loss of imprinting of IGF2 as an epigenetic marker for the risk of human cancer. Dis Markers 23: 105-112, 2007.
20. Abu-Amero S, Monk D, Apostolidou S, Stanier P and Moore G: Imprinted genes and their role in human fetal growth. Cytogenet Genome Res 113: 262-270, 2006.
21. Angiolini E, Fowden A, Coan P, Sandovici I, Smith P, Dean W, Burton G, Tycko B, Reik W, Sibley C and Constancia M: Regulation of placental efficiency for nutrient transport by imprinted genes. Placenta 27(Suppl A): S98-102, 2006.
22. Bressan FF, De Bern TH, Perecin F, Lopes FL, Ambrosio CE, Meirelles FV and Miglino MA: Unearthing the roles of imprinted genes in the placenta. Placenta 30: 823-834, 2009.
23. Feng W, Marquez RT, Lu Z, Liu J, Lu KH, Issa JP, Fishman DM, Yu Y and Bast RC Jr: Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer 112: 1489-1502, 2008.
24. Furukawa S, Haruta M, Arai Y, Honda S, Ohshima J, Sugawara W, Kageyama Y, Higashi Y, Nishida K, Tsunematsu Y, Nakadate H, Ishii M and Kaneko Y: Yolk sac tumor but not seminoma or teratoma is associated with abnormal epigenetic reprogramming pathway and shows frequent hypermethylation of various tumor suppressor genes. Cancer Sci 100: 698-708, 2009.
25. Jin M, Udagawa K, Miyagi E, Nakazawa T, Hirahara F, Yasumitsu H, Miyazaki K, Nagashima Y, Aoki I and Miyagi Y: Expression of serine proteinase inhibitor PP5/TFPI-2/MSPI decreases the invasive potential of human choriocarcinoma cells in vitro and in vivo. Gynecol Oncol 83: 325-333, 2001.
26. Udagawa K, Miyagi Y, Hirahara F, Miyagi E, Nagashima Y, Minaguchi H, Misugi K, Yasumitsu H and Miyazaki K: Specific expression of PP5/TFPI2 mRNA by syncytiotrophoblasts in human placenta as revealed by in situ hybridization. Placenta 19: 217-223, 1998.
27. Monk D, Wagschal A, Arnaud P, Muller PS, Parker-Katiraee L, Bourc'his D, Scherer SW, Feil R, Stanier P and Moore GE: Comparative analysis of human chromosome 7q21 and mouse proximal chromosome 6 reveals a placental-specific imprinted gene, TFPI2/Tfpi2, which requires EHMT2 and EED for allelic-silencing. Genome Res 18: 1270-1281, 2008.
28. Rak J, Milsom C, Magnus N and Yu J: Tissue factor in tumour progression. Best Pract Res Clin Haematol 22: 71-83, 2009.
29. Akashi T, Furuya Y, Ohta S and Fuse H: Tissue factor expression and prognosis in patients with metastatic prostate cancer. Urology 62: 1078-1082, 2003.
30. Abdulkadir SA, Carvalhal GF, Kaleem Z, Kisiel W, Humphrey PA, Catalona WJ and Milbrandt J: Tissue factor expression and angiogenesis in human prostate carcinoma. Hum Pathol 31: 443-447, 2000.
31. Kaushal V, Mukunyadzi P, Siegel ER, Dennis RA, Johnson DE and Kohli M: Expression of tissue factor in prostate cancer correlates with malignant phenotype. Appl Immunohistochem Mol Morphol 16: 1-6, 2008.
32. Konduri SD, Tasiou A, Chandrasekar N and Rao JS: Overexpression of tissue factor pathway inhibitor-2 (TFPI-2), decreases the invasiveness of prostate cancer cells in vitro. Int J Oncol 18: 127-131, 2001.
33. Ivanciu L, Gerard RD, Tang H, Lupu F and Lupu C: Adenovirus-mediated expression of tissue factor pathway inhibitor-2 inhibits endothelial cell migration and angiogenesis. Arterioscler Thromb Vasc Biol 27: 310-316, 2007.
34. Yanamandra N, Kondraganti S, Gondi CS, Gujrati M, Olivero WC, Dinh DH and Rao JS: Recombinant adeno-associated virus (rAAV) expressing TFPI-2 inhibits invasion, angiogenesis and tumor growth in a human glioblastoma cell line. Int J Cancer 115: 998-1005, 2005.
35. Jiang P, Watanabe H, Okada G, Ohtsubo K, Mouri H, Tsuchiyama T, Yao F and Sawabu N: Diagnostic utility of aberrant methylation of tissue factor pathway inhibitor 2 in pure pancreatic juice for pancreatic carcinoma. Cancer Sci 97: 1267-1273, 2006.
36. Sun Y, Xie M, Liu M, Jin D and Li P: Growth suppression of human laryngeal squamous cell carcinoma by adenovirus-mediated tissue factor pathway inhibitor gene 2. Laryngoscope 116: 596-601, 2006.
37. Atkin NB and Baker MC: Chromosome 7q deletions: observations on 13 malignant tumors. Cancer Genet Cytogenet 67: 123-125, 1993.
38. Glockner SC, Dhir M, Yi JM, McGarvey KE, Van Neste L, Louwagie J, Chan TA, Kleeberger W, de Bruine AP, Smits KM, Khalid-de Bakker CA, Jonkers DM, Stockbrugger RW, Meijer GA, Oort FA, Iacobuzio-Donahue C, Bierau K, Herman JG, Baylin SB, Van Engeland M, Schuebel KE and Ahuja N: Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res 69: 4691-4699, 2009.
39. Guo H, Lin Y, Zhang H, Liu J, Zhang N, Li Y, Kong D, Tang Q and Ma D: Tissue factor pathway inhibitor-2 was repressed by CpG hypermethylation through inhibition of KLF6 binding in highly invasive breast cancer cells. BMC Mol Biol 8: 110, 2007.
40. Kempaiah P, Chand HS and Kisiel W: Identification of a human TFPI-2 splice variant that is up-regulated in human tumor tissues. Mol Cancer 6: 20, 2007.
41. Rao CN, Segawa T, Navari JR, Xu L, Srivastava S, Moul JW and Phillips B: Methylation of TFPI-2 gene is not the sole cause of its silencing. Int J Oncol 22: 843-848, 2003.
42. Schulz WA, Elo JP, Florl AR, Pennanen S, Santourlidis S, Engers R, Buchardt M, Seifert HH and Visakorpi T: Genomewide DNA hypomethylation is associated with alterations on chromosome 8 in prostate carcinoma. Genes Chromosomes Cancer 35: 58-65, 2002.
43. Florl AR, Steinhoff C, Muller M, Seifert HH, Hader C, Engers R, Ackermann R and Schulz WA: Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. Br J Cancer 91: 985-994, 2004.
44. Hornstein M, Hoffmann MJ, Alexa A, Yamanaka M, Muller M, Jung V, Rahnenfuhrer J and Schulz WA: Protein phosphatase and TRAIL receptor genes as new candidate tumor genes on chromosome 8p in prostate cancer. Cancer Genomics Proteomics 5: 123-136, 2008.
45. Hoffmann MJ, Muller M, Engers R and Schulz WA: Epigenetic control of CTCFL/BORIS and OCT4 expression in urogenital malignancies. Biochem Pharmacol 72: 1577-1588, 2006.
46. Ruf W, Seftor EA, Petrovan RJ, Weiss RM, Gruman LM, Margaryan NV, Seftor RE, Miyagi Y and Hendrix MJ: Differential role of tissue factor pathway inhibitors 1 and 2 in melanoma vasculogenic mimicry. Cancer Res 63: 5381-5389, 2003.
47. Iversen N, Lindahl AK and Abildgaard U: Elevated TFPI in malignant disease: relation to cancer type and hypercoagulation. Br J Haematol 102: 889-895, 1998.
48. Iversen N, Lindahl AK and Abildgaard U: Elevated plasma levels of the factor Xa-TFPI complex in cancer patients. Thromb Res 105: 33-36, 2002.
49. Wojtukiewicz MZ, Sierko E, Zimnoch L, Kozlowski L and Kisiel W: Immunohistochemical localization of tissue factor pathway inhibitor-2 in human tumor tissue. Thromb Haemost 90: 140-146, 2003.
50. George J, Gondi CS, Dinh DH, Gujrati M and Rao JS: Restoration of tissue factor pathway inhibitor-2 in a human glioblastoma cell line triggers caspase-mediated pathway and apoptosis. Clin Cancer Res 13: 3507-3517, 2007.
51. Kondraganti S, Gondi CS, Gujrati M, McCutcheon I, Dinh DH, Rao JS and Olivero WC: Restoration of tissue factor pathway inhibitor inhibits invasion and tumor growth in vitro and in vivo in a malignant meningioma cell line. Int J Oncol 29: 25-32, 2006.
52. Udagawa K, Yasumitsu H, Esaki M, Sawada H, Nagashima Y, Aoki I, Jin M, Miyagi E, Nakazawa T, Hirahara F, Miyazaki K and Miyagi Y: Subcellular localization of PP5/TFPI-2 in human placenta: a possible role of PP5/TFPI-2 as an anti-coagulant on the surface of syncytiotrophoblasts. Placenta 23: 145-153, 2002.
53. Xu Z, Maiti D, Kisiel W and Duh EJ: Tissue factor pathway inhibitor-2 is up-regulated by vascular endothelial growth factor and suppresses growth factor-induced proliferation of endothelial cells. Arterioscler Thromb Vasc Biol 26: 2819-2825, 2006.
54. Wong CM, Ng YL, Lee JM, Wong CC, Cheung OF, Chan CY, Tung EK, Ching YP and Ng IO: Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma. Hepatology 45: 1129-1138, 2007.
55. Sato N, Parker AR, Fukushima N, Miyagi Y, Iacobuzio-Donahue CA, Eshleman JR and Goggins M: Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma. Oncogene 24: 850-858, 2005.
56. Hube F, Reverdiau P, Iochmann S, Rollin J, Cherpi-Antar C and Gruel Y: Transcriptional silencing of the TFPI-2 gene by promoter hypermethylation in choriocarcinoma cells. Biol Chem 384: 1029-1034, 2003.
57. Steiner FA, Hong JA, Fischette MR, Beer DG, Guo ZS, Chen GA, Weiser TS, Kassis ES, Nguyen DM, Lee S, Trepel JB and Schrump DS: Sequential 5-aza 2'-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells. Oncogene 24: 2386-2397, 2005.
58. Konduri SD, Srivenugopal KS, Yanamandra N, Dinh DH, Olivero WC, Gujrati M, Foster DC, Kisiel W, Ali-Osman F, Kondraganti S, Lakka SS and Rao JS: Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), a gene encoding an inhibitor of matrix metalloproteinases in human glioma cells. Oncogene 22: 4509-4516, 2003.
59. Blanchon L, Bocco JL, Gallot D, Gachon AM, Lemery D, Dechelotte P, Dastugue B and Sapin V: Co-localization of KLF6 and KLF4 with pregnancy-specific glycoproteins during human placenta development. Mech Dev 105: 185-189, 2001.
60. Narla G, Friedman SL and Martignetti JA: Kruppel cripples prostate cancer: KLF6 progress and prospects. Am J Pathol 162: 1047-1052, 2003.
61. Ono R, Nakamura K, Inoue K, Naruse M, Usami T, Wakisaka-Saito N, Hino T, Suzuki-Migishima R, Ogonuki N, Miki H, Kohda T, Ogura A, Yokoyama M, Kaneko-Ishino T and Ishino F: Deletion of Peg10, an imprinted gene acquired from a retrotransposon, causes early embryonic lethality. Nat Genet 38: 101-106, 2006.
62. Monk D, Arnaud P, Apostolidou S, Hills FA, Kelsey G, Stanier P, Feil R and Moore GE: Limited evolutionary conservation of imprinting in the human placenta. Proc Natl Acad Sci USA 103: 6623-6628, 2006.
63. Ono R, Shiura H, Aburatani H, Kohda T, Kaneko-Ishino T and Ishino F: Identification of a large novel imprinted gene cluster on mouse proximal chromosome 6. Genome Res 13: 1696-1705, 2003.
64. Suzuki S, Ono R, Narita T, Pask AJ, Shaw G, Wang C, Kohda T, Alsop AE, Marshall Graves JA, Kohara Y, Ishino F, Renfree MB and Kaneko-Ishino T: Retrotransposon silencing by DNA methylation can drive mammalian genomic imprinting. PLoS Genet 3: e55, 2007.
65. Stirzaker C, Song JZ, Davidson B and Clark SJ: Transcriptional gene silencing promotes DNA hypermethylation through a sequential change in chromatin modifications in cancer cells. Cancer Res 64: 3871-3877, 2004.
66. Leu YW, Yan PS, Fan M, Jin VX, Liu JC, Curran EM, Welshons WV, Wei SH, Davuluri RV, Plass C, Nephew KP and Huang TH: Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res 64: 8184-8192, 2004.
67. Strunnikova M, Schagdarsurengin U, Kehlen A, Garbe JC, Stampfer MR and Dammann R: Chromatin inactivation precedes de novo DNA methylation during the progressive epigenetic silencing of the RASSFIA promoter. Mol Cell Biol 25: 3923-3933, 2005.
68. Pantoja C, de Los Rios L, Matheu A, Antequera F and Serrano M: Inactivation of imprinted genes induced by cellular stress and tumorigenesis. Cancer Res 65: 26-33, 2005.
69. Feinberg AP, Cui H and Ohlsson R: DNA methylation and genomic imprinting: insights from cancer into epigenetic mechanisms. Semin Cancer Biol 12: 389-398, 2002.
70. Ohlsson R, Kanduri C, Whitehead J, Pfeifer S, Lobanenkov V, and Feinberg AP: Epigenetic variability and the evolution of human cancer. Adv Cancer Res 88: 145-168, 2003.